



## Supporting Information

for

*Angew. Chem. Int. Ed.* Z50153

© Wiley-VCH 2003

69451 Weinheim, Germany

## Thioglycoligases: Mutant Glycosidases for Thioglycoside Synthesis

Michael Jahn, Jennifer Marles, R. Antony J. Warren and Stephen G. Withers

### General:

$^1\text{H}$  and  $^{13}\text{C}$  NMR spectra were recorded on Bruker Avance-300 or Avance-400 Spectrometers. Chemical shifts are reported in  $\delta$  units (ppm) using residual  $^1\text{H}$  and  $^{13}\text{C}$  signals of the deuterated solvents as reference:  $\delta_{\text{H}}$  ( $\text{CDCl}_3$ ) 7.26,  $\delta_{\text{H}}$  ( $\text{CD}_3\text{OD}$ ) 3.31,  $\delta_{\text{C}}$  ( $\text{CDCl}_3$ ) 77.0,  $\delta_{\text{C}}$  ( $\text{CD}_3\text{OD}$ ) 49.0. Electrospray mass spectra were recorded on a PE Sciex API 300 LC/MS/MS instrument by direct injection of the compounds in a 1:1  $\text{CH}_3\text{CN}/\text{H}_2\text{O}$  solution. Melting points were determined with a Mel-Temp II apparatus and are not corrected. Silica gel 60 (230-400 mesh) from SiliCycle was used for column chromatography. The petroleum ether used for column chromatography had a boiling point range from 35-60°C. Amberlite IR-120PLUS from Aldrich was transformed into the  $\text{H}^+$ -form before use. All reagents and solvents were purchased from Aldrich, Fluka, Sigma or Fisher Scientific. Solvents were dried over  $\text{CaH}_2$  ( $\text{CH}_2\text{Cl}_2$ , pyridine, toluene, acetonitrile), over Mg (methanol) or over molecular sieves 4Å (DMF). All reactions were carried out under a dry nitrogen atmosphere.

### Chemical Synthesis of deoxythio sugar acceptors:

#### *p*-Nitrophenyl 2,3,6-tri-*O*-benzoyl- $\beta$ -*D*-galactopyranoside:

Benzoyl chloride (1.50 ml, 1.82 g, 12.9 mmol) was added dropwise to a solution of *p*-nitrophenyl  $\beta$ -*D*-galactopyranoside (1.00 g, 3.32 mmol) in DMF (15 ml) and pyridine (15 ml) at -20°C. After stirring for 5 h at -5°C another 0.30 ml of benzoyl chloride (0.36 g, 2.59 mmol) was added dropwise, and the solution was stirred for 2 h at -5°C. Water (10 ml) was added and the mixture was concentrated by evaporation in vacuo. The residue was

dissolved in CH<sub>2</sub>Cl<sub>2</sub>, and the organic phase was washed sequentially with saturated aqueous NaHCO<sub>3</sub>, 1 M HCl and brine, dried over MgSO<sub>4</sub>, filtered and concentrated in vacuo. Column chromatography (toluene → 4:1 toluene/EtOAc) followed by crystallization from hot toluene yielded *p*-nitrophenyl 2,3,6-tri-*O*-benzoyl-β-D-galactopyranoside (850 mg, 1.39 mmol, 42%); mp 180-181°C; <sup>1</sup>H-NMR (400 MHz): δ<sub>H</sub> (CDCl<sub>3</sub>): 8.05 (m, 2 H, Ar), 8.0 - 7.3 (m, 15 H, 3xBz), 7.06 (m, 2 H, Ar), 6.10 (dd, 1 H, *J*<sub>2,3</sub> 10.3 Hz, *J*<sub>2,1</sub> 7.9 Hz, H-2), 5.48 (dd, 1 H, *J*<sub>3,2</sub> 10.3 Hz, *J*<sub>3,4</sub> 3.2 Hz, H-3), 5.40 (d, 1 H, *J*<sub>1,2</sub> 7.9 Hz, H-1), 4.76 (dd, 1 H, *J*<sub>6,6</sub> 11.7 Hz, *J*<sub>6,5</sub> 5.1 Hz, H-6), 4.68 (dd, 1 H, *J*<sub>6,6</sub> 11.7 Hz, *J*<sub>6,5</sub> 7.7 Hz, H-6), 4.47 (m, 1 H, H-4), 4.31 (m, 1 H, H-5), 2.66 (d, 1 H, *J*<sub>OH,4</sub> 4.5 Hz, OH); <sup>13</sup>C-NMR (75 MHz): δ<sub>C</sub> (CDCl<sub>3</sub>): 166.4, 165.8, 165.3, 161.3, 143.0, 133.7, 133.5, 129.9, 129.7, 129.7, 129.3, 129.0, 128.6, 128.6, 128.5, 128.5, 125.6, 116.8, 98.8, 73.9, 73.2, 69.0, 67.1, 63.0; ESI-MS: *m/z* = 636.5 [M + Na]<sup>+</sup> (expected for C<sub>33</sub>H<sub>27</sub>NO<sub>11</sub>Na<sup>+</sup>: *m/z* = 636.2).

*p*-Nitrophenyl 4-*S*-acetyl-2,3,6-tri-*O*-benzoyl-4-deoxy-4-thio-β-D-glucopyranoside:

Trifluoromethanesulfonic anhydride (0.44 ml, 0.75 g, 2.7 mmol) was added dropwise to a solution of *p*-nitrophenyl 2,3,6-tri-*O*-benzoyl-β-D-galactopyranoside (813 mg, 1.33 mmol) in 20 ml CH<sub>2</sub>Cl<sub>2</sub> and 1.2 ml pyridine at 0°C. After 1 h at 0°C, CH<sub>2</sub>Cl<sub>2</sub> (50 ml) was added, and the organic layer was washed with saturated aqueous NaHCO<sub>3</sub>, 1M HCl and brine, dried over MgSO<sub>4</sub>, filtered and concentrated in vacuo to give 990 mg of a yellowish solid (100%). Potassium thioacetate (460 mg, 4.0 mmol) and HMPA (10 ml) were added, and the suspension was stirred at RT for 1 h. A mixture of EtOAc/Et<sub>2</sub>O (1:1, 50 ml) was added, and the organic layer was washed twice with water, with brine, dried over MgSO<sub>4</sub>, filtered and concentrated in vacuo. Column chromatography (19:1 → 3:1 PE/EtOAc) and crystallization from hot EtOAc yielded *p*-nitrophenyl 4-*S*-acetyl-2,3,6-tri-*O*-benzoyl-4-deoxy-4-thio-β-D-glucopyranoside as a white powder (520 mg, 59%); mp 249°C (degradation); <sup>1</sup>H-NMR (300 MHz): δ<sub>H</sub> (CDCl<sub>3</sub>): 8.06 (m, 2 H, Ar), 8.02 - 7.31 (m, 15 H, 3xBz), 7.02 (m, 2 H, Ar), 5.84 (dd, 1 H, *J*<sub>3,4</sub> 10.8 Hz, *J*<sub>3,2</sub> 9.3 Hz, H-3), 5.73 (dd, 1 H, *J*<sub>2,3</sub> 9.3 Hz, *J*<sub>2,1</sub> 7.6 Hz, H-2), 5.43 (d, 1 H, *J*<sub>1,2</sub> 7.6 Hz, H-1), 4.79 (dd, 1 H, *J*<sub>6,6</sub> 12.0 Hz, *J*<sub>6,5</sub> 2.2 Hz, H-6), 4.54 (dd, 1 H, *J*<sub>6,6</sub> 12.0 Hz, *J*<sub>6,5</sub> 7.2 Hz, H-6), 4.37 (m, 1 H, H-5), 4.10 (t, 1 H,

$J_{4,5}=J_{4,3}$  10.8 Hz, H-4), 2.28 (s, 3 H, Ac);  $^{13}\text{C-NMR}$  (75 MHz):  $\delta_{\text{C}}$  ( $\text{CDCl}_3$ ): 192.7, 165.9, 165.6, 165.0, 161.1, 143.1, 138.8, 133.6, 133.6, 129.9, 129.8, 129.7, 129.4, 128.8, 128.6, 128.5, 128.4, 125.6, 116.8, 98.3, 73.7, 72.5, 71.2, 63.7, 44.3, 30.8; ESI-MS:  $m/z = 694.0$  [ $\text{M} + \text{Na}$ ] $^+$  (expected for  $\text{C}_{35}\text{H}_{29}\text{NO}_{11}\text{SNa}^+$ :  $m/z = 694.1$ ).

*p*-Nitrophenyl 4-deoxy-4-thio- $\beta$ -D-glucopyranoside (**1**):

A solution of *p*-nitrophenyl 4-*S*-acetyl-2,3,6-tri-*O*-benzoyl-4-deoxy-4-thio- $\beta$ -D-glucopyranoside (230 mg, 0.34 mmol) in 10 ml MeOH containing catalytic amounts of MeONa was stirred for 3 h at RT. The mixture was neutralized with Amberlite IR-120PLUS ( $\text{H}^+$ -form). After filtration, DTT (280 mg, 1.8 mmol) in 2 ml of degassed water was added, and  $\text{N}_2$  was bubbled through the solution for 5 min. After stirring under  $\text{N}_2$  overnight the mixture was concentrated in vacuo. Column chromatography (3:2 toluene/EtOAc  $\rightarrow$  EtOAc) afforded **1** as a white powder (80 mg, 0.25 mmol, 74%);  $^1\text{H-NMR}$  (400 MHz):  $\delta_{\text{H}}$  ( $\text{d}_4$ -MeOH): 8.22 (m, 2 H, Ar), 7.23 (m, 2 H, Ar), 5.10 (d, 1 H,  $J_{1,2}$  7.6 Hz, H-1), 3.94 (dd, 1 H,  $J_{6,6}$  12.3 Hz,  $J_{6,5}$  1.9 Hz, H-6), 3.84 (dd, 1 H,  $J_{6,6}$  12.3 Hz,  $J_{6,5}$  4.8 Hz, H-6), 3.62 (m, 1 H, H-5), 3.49 (dd, 1 H,  $J_{2,3}$  9 Hz,  $J_{2,1}$  7.6, H-2), 3.41 (dd, 1 H,  $J_{3,4}$  10.2 Hz,  $J_{3,2}$  9.0 Hz, H-3), 2.84 (t, 1 H,  $J_{4,5}=J_{4,3}$  10.2 Hz, H-4);  $^{13}\text{C-NMR}$  (75 MHz):  $\delta_{\text{C}}$  ( $\text{d}_4$ -MeOH): 163.9, 143.9, 126.6, 117.7, 101.5, 79.8, 78.8, 75.7, 62.9, 43.0; ESI-MS:  $m/z = 340.0$  [ $\text{M} + \text{Na}$ ] $^+$  (expected for  $\text{C}_{12}\text{H}_{15}\text{NO}_7\text{SNa}^+$ :  $m/z = 340.1$ ).

*p*-Nitrophenyl 2,3-di-*O*-benzoyl- $\alpha$ -L-arabinopyranoside:

Benzoyl chloride (1.0 ml, 1.25 g, 8.7 mmol) was added dropwise to a solution of *p*-nitrophenyl  $\alpha$ -L-arabinopyranoside (1.00 g, 3.8 mmol) in DMF (30 ml) and pyridine (10 ml) at  $-20^\circ\text{C}$ . The mixture was allowed to warm to RT overnight while stirring and worked up as *p*-nitrophenyl 2,3,6-tri-*O*-benzoyl- $\beta$ -D-galactopyranoside. Column chromatography (5:1  $\rightarrow$  2:1 PE/EtOAc) and crystallization from EtOAc/heptane yielded *p*-nitrophenyl 2,3-di-*O*-benzoyl- $\alpha$ -L-arabinopyranoside as a white powder (520 mg, 1.11 mmol, 29%); mp  $150$ - $151^\circ\text{C}$ ;  $^1\text{H-NMR}$  (400 MHz):  $\delta_{\text{H}}$  ( $\text{CDCl}_3$ ): 8.18 (m, 2 H, Ar), 8.13-7.40 (m, 10 H, 2xBz), 7.08 (m, 2 H, Ar), 5.80 (dd, 1 H,  $J_{2,3}$  6.4 Hz,  $J_{2,1}$  4.2 Hz, H-2), 5.55 (dd, 1 H,  $J_{3,2}$  6.4

Hz,  $J_{3,4}$  3.3 Hz, H-3), 5.52 (d, 1 H,  $J_{1,2}$  4.2 Hz, H-1), 4.46 (m, 1 H, H-4), 4.17 (dd, 1 H,  $J_{5,5}$  11.9 Hz,  $J_{5,4}$  7.0 Hz, H-5), 3.90 (dd, 1 H,  $J_{5,5}$  11.9 Hz,  $J_{5,4}$  3.4 Hz, H-5), 2.40 (d, 1 H,  $J_{\text{OH},4}$  5.3 Hz, OH);  $^{13}\text{C}$ -NMR (100 MHz):  $\delta_{\text{C}}$  ( $\text{CDCl}_3$ ): 165.9, 165.0, 161.2, 142.9, 133.8, 133.7, 129.9, 129.8, 128.8, 128.6, 128.6, 125.8, 116.5, 96.8, 71.4, 69.0, 65.1, 62.9; ESI-MS:  $m/z$  = 502.0  $[\text{M} + \text{Na}]^+$  (expected for  $\text{C}_{25}\text{H}_{21}\text{NO}_9\text{Na}^+$ :  $m/z$  = 502.1).

*p*-Nitrophenyl 4-*S*-acetyl-2,3-di-*O*-benzoyl-4-deoxy-4-thio- $\beta$ -*D*-xylopyranoside:

The partially protected glycoside *p*-nitrophenyl 2,3-di-*O*-benzoyl- $\alpha$ -*L*-arabinopyranoside (340 mg, 0.71 mmol) was treated as described for the preparation of *p*-nitrophenyl 4-*S*-acetyl-2,3,6-tri-*O*-benzoyl-4-deoxy-4-thio- $\beta$ -*D*-glucopyranoside. Column chromatography (6:1  $\rightarrow$  2:1 PE/EtOAc) gave *p*-nitrophenyl 4-*S*-acetyl-2,3-di-*O*-benzoyl-4-deoxy-4-thio- $\beta$ -*D*-xylopyranoside as a white foam (215 mg, 0.4 mmol, 56%);  $^1\text{H}$ -NMR (400 MHz):  $\delta_{\text{H}}$  ( $\text{CDCl}_3$ ): 8.19 (m, 2 H, Ar), 8.1-7.35 (m, 10 H, 2xBz), 7.09 (m, 2 H, Ar), 5.60 (m, 1 H, H-3), 5.57 (m, 1 H, H-2), 5.50 (d, 1 H,  $J_{1,2}$  4.9 Hz, H-1), 4.42 (dd, 1 H,  $J_{5,5}$  12.2 Hz,  $J_{5,4}$  4.2 Hz, H-5), 4.07 (m, 1 H, H-4), 3.75 (dd, 1 H,  $J_{5,5}$  12.2 Hz,  $J_{5,4}$  7.5 Hz, H-5), 2.35 (s, 3 H, Ac);  $^{13}\text{C}$ -NMR (100 MHz):  $\delta_{\text{C}}$  ( $\text{CDCl}_3$ ): 193.4, 165.2, 165.0, 161.1, 143.0, 133.6, 129.9, 128.9, 128.8, 128.5, 125.8, 116.6, 97.7, 70.2, 69.8, 63.4, 41.3, 30.7; ESI-MS:  $m/z$  = 560.0  $[\text{M} + \text{Na}]^+$  (expected for  $\text{C}_{27}\text{H}_{23}\text{NO}_9\text{SNa}^+$ :  $m/z$  = 560.1).

*p*-Nitrophenyl 4-deoxy-4-thio- $\beta$ -*D*-xylopyranoside (**2**):

*p*-Nitrophenyl 4-*S*-acetyl-2,3-di-*O*-benzoyl-4-deoxy-4-thio- $\beta$ -*D*-xylopyranoside (190 mg, 0.35 mmol) was deprotected as described for compound **1**. Column chromatography (1:1  $\rightarrow$  1:3 PE/EtOAc) gave **2** as a white powder (70 mg, 0.24 mmol, 69%);  $^1\text{H}$ -NMR (400 MHz):  $\delta_{\text{H}}$  ( $d_4$ -MeOH): 8.20 (m, 2 H, Ar), 7.18 (m, 2 H, Ar), 5.03 (d, 1 H,  $J_{1,2}$  7.6 Hz, H-1), 3.98 (dd, 1 H,  $J_{5,5}$  11.8 Hz,  $J_{5,4}$  5.0 Hz, H-5), 3.52 (t, 1 H,  $J_{5,5}=J_{5,4}$  11.8 Hz, H-5), 3.44 (dd, 1 H,  $J_{2,3}$  8.9 Hz,  $J_{2,1}$  7.6 Hz, H-2), 3.32 (m, 1 H, H-3), 2.84 (m, 1 H, H-4);  $^{13}\text{C}$ -NMR (100 MHz):  $\delta_{\text{C}}$  ( $d_4$ -MeOH): 163.7, 143.9, 126.6, 117.6, 102.3, 78.6, 75.9, 69.2, 42.0; ESI-MS:  $m/z$  = 310.0  $[\text{M} + \text{Na}]^+$  (expected for  $\text{C}_{11}\text{H}_{13}\text{NO}_6\text{SNa}^+$ :  $m/z$  = 310.0).

### Enzymatic synthesis of thiooligosaccharides:

The deoxythio sugars **1** or **2** (20 mM), the DNP-donors 2,4-dinitrophenyl  $\beta$ -D-glucopyranoside (DNP-Glc) or 2,5-dinitrophenyl  $\beta$ -D-mannopyranoside (DNP-Man) (30 mM) and the mutant enzymes Abg E171A or Man2A E429A ( $\sim 1$  mg ml<sup>-1</sup>) were incubated for  $\sim 3$  h at RT in phosphate buffer (80 mM). DNP-Glc or DNP-Man was added to a total concentration of 45 mM, and the solution was incubated at RT for  $\sim 1$  h. After lyophilization standard per-*O*-acetylation with pyridine/Ac<sub>2</sub>O and subsequent workup was performed. The final purification by column chromatography (9:1  $\rightarrow$  1:1 toluene/EtOAc) yielded products **3-6**.

*p*-Nitrophenyl (2,3,4,6-tetra-*O*-acetyl- $\beta$ -D-glucopyranosyl)-(1 $\rightarrow$ 4)-*S*-2,3,6-tri-*O*-acetyl-4-deoxy-4-thio- $\beta$ -D-glucopyranoside (**3**):

25 mg (64%); mp 161.5-162°C (hot toluene); <sup>1</sup>H-NMR (400 MHz):  $\delta_{\text{H}}$  (CDCl<sub>3</sub>): 8.19 (m, 2 H, Ar), 7.09 (m, 2 H, Ar), 5.29 - 5.16 (m, 4 H, H-1, H-2, H-3', H-3), 5.06 (t, 1 H,  $J_{4,3}=J_{4,5}$  9.8 Hz, H-4'), 4.94 (t, 1 H,  $J_{2,1'}=J_{2,3'}$  9.6 Hz, H-2'), 4.77 (d, 1 H,  $J_{1,2'}$  10 Hz, H-1'), 4.64 (dd, 1 H,  $J_{6,6}$  12.1 Hz,  $J_{6,5}$  1.7 Hz, H-6), 4.38 (dd, 1 H,  $J_{6,6}$  12.1 Hz,  $J_{6,5}$  5.5 Hz, H-6), 4.31 (dd, 1 H,  $J_{6,6'}$  12.4 Hz,  $J_{6,5'}$  2.2 Hz, H-6'), 4.13 (dd, 1 H,  $J_{6,6'}$  12.4 Hz,  $J_{6,5'}$  4.8 Hz, H-6'), 4.06 (m, 1 H, H-5), 3.75 (m, 1 H, H-5'), 3.05 (t, 1 H,  $J_{4,5}=J_{4,3}$  10.6 Hz, H-4), 2.10, 2.09, 2.07, 2.06, 2.04, 2.02, 2.00 (7xs, 21 H, 7xAc); <sup>13</sup>C-NMR (100 MHz):  $\delta_{\text{C}}$  (CDCl<sub>3</sub>): 170.4, 170.1, 170.0, 170.0, 169.3, 169.3, 169.2, 161.3, 143.2, 125.7, 116.7, 98.0, 81.7, 75.9, 74.6, 73.6, 72.4, 70.3, 69.9, 68.1, 63.3, 61.9, 45.8, 20.7-20.4 (7x); ESI-MS:  $m/z$  = 796.0 [M + Na]<sup>+</sup> (expected for C<sub>32</sub>H<sub>39</sub>NO<sub>19</sub>SNa<sup>+</sup>:  $m/z$  = 796.2).

*p*-Nitrophenyl (2,3,4,6-tetra-*O*-acetyl- $\beta$ -D-glucopyranosyl)-(1 $\rightarrow$ 4)-*S*-2,3-di-*O*-acetyl-4-deoxy-4-thio- $\beta$ -D-xylopyranoside (**4**):

29 mg (79%); mp 122-123°C (EtOAc/heptane); <sup>1</sup>H-NMR (400 MHz):  $\delta_{\text{H}}$  (CDCl<sub>3</sub>): 8.20 (m, 2 H, Ar), 7.07 (m, 1 H, Ar), 5.21 - 5.11 (m, 4 H, H-1, H-2, H-3, H-3'), 5.07 (t, 1 H,  $J_{4,3}=J_{4,5}$  9.9 Hz, H-4'), 5.00 (dd, 1 H,  $J_{2,1'}$  10 Hz,  $J_{2,3'}$  9.3 Hz, H-2'), 4.63 (d, 1 H,  $J_{1,2'}$  10

Hz, H-1'), 4.29 (dd, 1 H,  $J_{5,5}$  12.4 Hz,  $J_{5,4}$  4.5 Hz, H-5), 4.19 (d, 2 H,  $J_{6,5'}$  3.5 Hz, 2xH-6'), 3.74 (dt, 1 H,  $J_{5',4'}$  9.9 Hz and  $J_{5',6'}$  3.5 Hz, H-5'), 3.65 (dd, 1 H,  $J_{5,5}$  12.4 Hz,  $J_{5,4}$  9.6 Hz, H-5), 3.23 (m, 1 H, H-4), 2.10, 2.06, 2.05, 2.03, 2.02, 2.00 (6xs, 18 H, 6xAc);  $^{13}\text{C}$ -NMR (100 MHz):  $\delta_{\text{C}}$  ( $\text{CDCl}_3$ ): 170.4, 170.0, 169.9, 169.2, 169.2, 169.0, 161.1, 143.0, 125.7, 116.5, 98.1, 81.9, 76.0 (x2), 73.6, 71.3, 69.9, 67.9, 65.6, 61.8, 42.7, 20.5 (6x); ESI-MS:  $m/z$  = 724.5  $[\text{M} + \text{Na}]^+$  (expected for  $\text{C}_{29}\text{H}_{35}\text{NO}_{17}\text{SNa}^+$ :  $m/z$  = 724.2).

*p*-Nitrophenyl (2,3,4,6-tetra-*O*-acetyl- $\beta$ -*D*-mannopyranosyl)-(1 $\rightarrow$ 4)-*S*-2,3,6-tri-*O*-acetyl-4-deoxy-4-thio- $\beta$ -*D*-glucopyranoside (**5**):

5 mg (35%);  $^1\text{H}$ -NMR (400 MHz):  $\delta_{\text{H}}$  ( $\text{CDCl}_3$ ): 8.20 (m, 2 H, Ar), 7.09 (m, 2 H, Ar), 5.36 (dd, 1 H,  $J_{2,3'}$  3.5 Hz,  $J_{2,1'}$  1 Hz, H-2'), 5.32 - 5.17 (m, 4 H, H-1, H-2, H-3, H-4'), 5.09 (dd, 1 H,  $J_{3,4'}$  10.1 Hz,  $J_{3,2'}$  3.5 Hz, H-3'), 4.98 (d, 1 H,  $J_{1,2'}$  1 Hz, H-1'), 4.61 (dd, 1 H,  $J_{6,6}$  12.2 Hz,  $J_{6,5}$  2.1 Hz, H-6), 4.46 (dd, 1 H,  $J_{6,6}$  12.2 Hz,  $J_{6,5}$  5.4 Hz, H-6), 4.33 (dd, 1 H,  $J_{6,6'}$  12.4 Hz,  $J_{6,5'}$  2.4 Hz, H-6'), 4.15 (dd, 1 H,  $J_{6,6'}$  12.4 Hz,  $J_{6,5'}$  5.5 Hz, H-6'), 4.08 (m, 1 H, H-5), 3.75 (m, 1 H, H-5'), 3.07 (t, 1 H,  $J_{4,5}=J_{4,3}$  10.7 Hz, H-4), 2.20, 2.12, 2.10, 2.07, 2.06, 2.06, 1.98 (7xs, 21 H, 7xAc);  $^{13}\text{C}$ -NMR (75 MHz):  $\delta_{\text{C}}$  ( $\text{CDCl}_3$ ): 170.5, 170.3, 170.3, 170.0, 169.8, 169.6, 169.2, 161.2, 143.2, 125.7, 116.6, 98.1, 79.3, 74.3, 72.1, 71.5, 69.9, 69.7, 65.7, 45.1, 20.6 (7x); ESI-MS:  $m/z$  = 796.0  $[\text{M} + \text{Na}]^+$  (expected for  $\text{C}_{32}\text{H}_{39}\text{NO}_{19}\text{SNa}^+$ :  $m/z$  = 796.2).

*p*-Nitrophenyl (2,3,4,6-tetra-*O*-acetyl- $\beta$ -*D*-mannopyranosyl)-(1 $\rightarrow$ 4)-*S*-2,3-di-*O*-acetyl-4-deoxy-4-thio- $\beta$ -*D*-xylopyranoside (**6**):

25 mg (82%);  $^1\text{H}$ -NMR (400 MHz):  $\delta_{\text{H}}$  ( $\text{CDCl}_3$ ): 8.20 (m, 2 H, Ar), 7.07 (m, 2 H, Ar), 5.45 (d, 1 H,  $J_{2,3'}$  3.5 Hz, H-2'), 5.26-5.12 (m, 4 H, H-1, H-2, H-3, H-4'), 5.07 (dd, 1 H,  $J_{3,4'}$  10.1 Hz,  $J_{3,2'}$  3.5 Hz, H-3'), 4.87 (s, 1 H, H-1'), 4.28-4.15 (m, 3 H, H-5, H-6', H-6'), 3.75 (m, 1 H, H-5'), 3.66 (dd, 1 H,  $J_{5,5}$  12.4 Hz,  $J_{5,4}$  10.0 Hz, H-5), 3.28 (m, 1 H, H-4), 2.20, 2.10, 2.08, 2.06, 2.04, 2.03, 1.97 (6xs, 18 H, 6xAc);  $^{13}\text{C}$ -NMR (75 MHz):  $\delta_{\text{C}}$  ( $\text{CDCl}_3$ ): 170.4, 170.2, 170.0, 169.9, 169.6, 169.3, 161.1, 143.1, 125.8, 116.5, 98.3, 79.8, 76.8, 71.7, 71.5, 70.9,

69.8, 65.5 (2x), 62.6, 43.0, 20.5 (6x); ESI-MS:  $m/z = 724.5$  ( $M + Na$ )<sup>+</sup> (expected for  $C_{29}H_{35}NO_{17}SNa^+$ :  $m/z = 724.2$ ).



Competition study for evaluation of relative rates:

pNP-Xyl (5.5 mM), **2** (5.5 mM), DNP-Man (3.75 mM) and Man2A E429A (~1 mg ml<sup>-1</sup>) were incubated in phosphate buffer (50 mM, pH 6.8) for 3 h at RT. After removal of an aliquot DNP-Man was added to a final concentration of 22 mM. After 5 h at RT another aliquot was taken. The aliquots were diluted 1:3 with acetonitrile and centrifuged before applying to the HPLC.

HPLC analysis was performed using a Waters 600E multisolvent delivery system with acetonitrile (A)/ water (B) as mobile phase (linear gradient: 80% A → 60% A in 15 min, flow: 1 ml min<sup>-1</sup>), a Waters 2486 Dual  $\lambda$  Absorbance Detector (detection at 280 nm), a TOSO HAAS Amide 80 column (4.6 x 250 mm) and Millennium 3.20 software.